Abbott Laboratories (ABT) Cash from Financing Activities (2009 - 2026)

Abbott Laboratories' Cash from Financing Activities history runs 18 years deep, the most recent figure standing at $17.3 billion for Q1 2026.

• In Q1 2026, Cash from Financing Activities rose 942.48% year-over-year to $17.3 billion; the TTM figure through Mar 2026 stood at $13.1 billion (up 307.85% YoY), while the FY2025 annual figure was -$6.3 billion, down 16.75% from the prior year.
• Cash from Financing Activities came in at $17.3 billion for Q1 2026 at Abbott Laboratories, up from -$1.4 billion in the prior quarter.
• In the past five years, Cash from Financing Activities ranged from a high of $17.3 billion in Q1 2026 to a low of -$3.8 billion in Q1 2022.
• A 5-year average of -$536.9 million and a median of -$1.5 billion in 2022 frame the typical range for Cash from Financing Activities.
• Across the five-year window, Cash from Financing Activities slumped 295.35% in 2022 and jumped 942.48% in 2026, its largest moves.
• Abbott Laboratories' Cash from Financing Activities stood at -$1.5 billion in 2022, then slumped by 40.84% to -$2.1 billion in 2023, then increased by 9.31% to -$1.9 billion in 2024, then grew by 24.93% to -$1.4 billion in 2025, then surged by 1339.3% to $17.3 billion in 2026.
• According to Business Quant data, Cash from Financing Activities over the past three periods registered $17.3 billion, -$1.4 billion, and -$1.8 billion for Q1 2026, Q4 2025, and Q3 2025 respectively.

Peer Comparison